Tacrine therapy

• US 5,698,224 A
• Filed: 06/27/1994
• Issued: 12/16/1997
• Est. Priority Date: 06/27/1994
• Status: Expired due to Fees

• Current Assignee: Encinal Pharmaceutical Investments, LLC, The United States of America Secretary of Army
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Kidney, David J., Guittard, George V., Wong, Patrick S. -L., Gumucio, Fernando E., Childers, Jerry D.
• Primary Examiner(s): Mullis, Jeffrey C.
• Application Number:
  US08/266,045
• Time in Patent Office: 1,268 Days
• Field of Search: 424/439, 424/451, 424/452, 424/457, 424/463, 424/486, 424/488, 424/468, 424/471, 424/472, 424/480
• US Class Current: 424/468
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0004 Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
• CPC Class Codes: A61K 9/2018 Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
• CPC Class Codes: A61K 9/2027 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• CPC Class Codes: A61K 9/2054 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

A dosage form is disclosed for administering 10 ng to 1200 mg tacrine to a patient in need of tacrine therapy.

Claims

1. An osmotic dosage form for delivering tacrine to the gastrointestinal tract of an Alzheimer'"'"'s patient, wherein the osmotic dosage form comprises:

(a) a tacrine composition comprising 86.15 mg of tacrine hydrochloride, 86.15 mg of mannitol, 7.25 mg of poly(vinylpyrrolidone) and 1.81 mg of magnesium stearate;

(b) a semipermeable wall coated around the tacrine composition, comprising 80 wt % cellulose acetate and 20 wt % poly(vinylpyrrolidone), and,

(c) an exit passageway in the wall that connects the tacrine composition with the exterior of the dosage form for delivering tacrine over 24 hours.

2. The osmotic dosage form for delivering tacrine according to claim 1, wherein a dose of tacrine is coated on the exterior surface of the semipermeable wall.